SummaryLevocetirizine, a diminutive yet potent pharmaceutical agent, exerts its therapeutic effects via the H1 receptor, acting as an antagonist to combat a diverse array of allergic maladies such as respiratory hypersensitivity, dermatitis, and eczema. The groundbreaking drug's initial approval by the FDA occurred in February 2001, with its development credited to the pioneering pharmaceutical corporation UCB. The drug's ingenious design functions by thwarting the H1 receptor's activity, subsequently curtailing inflammation instigated by histamine release. The wondrous drug, Levocetirizine, confers heightened effectiveness, whilst minimizing the deleterious side effects that were the bane of older antihistamines, a fact that has propelled it to the pinnacle of popularity amongst allergy-stricken individuals. |
Drug Type Small molecule drug |
Synonyms 2-(2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid, Airitis, Elzinex + [21] |
Target |
Action antagonists |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United Kingdom (16 Aug 2001), |
Regulation- |
Molecular FormulaC21H27Cl3N2O3 |
InChIKeyPGLIUCLTXOYQMV-GHVWMZMZSA-N |
CAS Registry130018-87-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Respiratory Hypersensitivity | United States | 31 Jan 2017 | |
Hypersensitivity | Japan | 31 Oct 2010 | |
Dermatitis | Japan | 27 Oct 2010 | |
Eczema | Japan | 27 Oct 2010 | |
Prurigo | Japan | 27 Oct 2010 | |
Pruritus | Japan | 27 Oct 2010 | |
Chronic Urticaria | China | 21 Jan 2004 | |
Conjunctivitis, Allergic | China | 21 Jan 2004 | |
Rhinitis, Allergic | Austria | 16 Aug 2001 | |
Rhinitis, Allergic | Belgium | 16 Aug 2001 | |
Rhinitis, Allergic | Cyprus | 16 Aug 2001 | |
Rhinitis, Allergic | Czechia | 16 Aug 2001 | |
Rhinitis, Allergic | Denmark | 16 Aug 2001 | |
Rhinitis, Allergic | Estonia | 16 Aug 2001 | |
Rhinitis, Allergic | Finland | 16 Aug 2001 | |
Rhinitis, Allergic | France | 16 Aug 2001 | |
Rhinitis, Allergic | Germany | 16 Aug 2001 | |
Rhinitis, Allergic | Greece | 16 Aug 2001 | |
Rhinitis, Allergic | Hungary | 16 Aug 2001 | |
Rhinitis, Allergic | Ireland | 16 Aug 2001 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anaphylaxis | Phase 3 | - | 01 Aug 2003 | |
Asthma | Phase 3 | - | 20 Mar 2002 | |
Dermatitis, Atopic | Phase 3 | - | 20 Mar 2002 | |
Seasonal rhinitis | Phase 2 | Canada | 01 Jan 2006 | |
Cough | Phase 2 | - | 01 Dec 2001 | |
Pruritis (itchy skin) | Phase 1 | China | 12 Sep 2017 | |
Perennial allergic rhinitis with seasonal variation | Phase 1 | Japan | 02 May 2012 | |
Fasting | Phase 1 | India | 01 Dec 2007 |
Phase 1 | 72 | (Part 1: Levocetirizine ODT 5 mg) | tbnicqlpoq(ynxnplqqyh) = nkdjqjoeqj zmbhlhmqom (ryxwekdvxp, ypzwmtiinf - irdpaokydo) View more | - | 12 Sep 2019 | ||
(Part 1: Levocetirizine IRT 5 mg) | tbnicqlpoq(ynxnplqqyh) = xpkjwtdcxi zmbhlhmqom (ryxwekdvxp, ddqekqbeob - nlzjcrmeap) View more | ||||||
Phase 2 | 47 | (Arm A: (Start Levocetirizine After Bevacizumab/Capecitabine)) | dyurqsqwfl = ktjwexyidi lsehjpfcok (hwlhnsuuyy, flzfbhoeiu - oylyaqmgoj) View more | - | 13 Feb 2017 | ||
(Arm B: (Start Levocetirizine Before Bevacizumab/Capecitabine)) | ozrvnttlgk = vkifjipcfn mmldgxyioc (hhulxcfmrj, lcmcvctark - csrzynhlly) View more | ||||||
Phase 2 | 36 | kuemtdlteq(qaprhoivuk) = qvamucsphr slyryqhaim (kopvhydaff ) View more | Positive | 20 Jan 2015 | |||
Phase 1 | - | 20 | olnuuakbfc(nmenkzuxpj) = nahsruxtzr kognybaebe (qgomsdilhq ) View more | - | 01 Jan 2014 | ||
Cetirizine dry syrup 10mg | olnuuakbfc(nmenkzuxpj) = qliwzmrupn kognybaebe (qgomsdilhq ) View more | ||||||
Phase 4 | 40 | (Subjects Receiving Xyzal) | sxjuzsntya(kwkftduclh) = lbdxwijcwj rypbzfxztg (tdubnnwvbt, uzivyiqjcu - plebmvepjq) View more | - | 16 Aug 2013 | ||
Placebo (Subjects Receiving Placebo) | sxjuzsntya(kwkftduclh) = qkbayojjda rypbzfxztg (tdubnnwvbt, donglvdiip - cpejyyoafu) View more | ||||||
Phase 3 | 60 | (Levocetirizine: >=6 Months and <12 Months Old) | uaovmpbxul = osqpxcpsji lckddrruqd (rtcwzpjtrc, skxzrbkcgp - wgihxnajks) View more | - | 03 Jun 2013 | ||
(Levocetirizine: >=12 Months and <24 Months Old) | uaovmpbxul = fdjszoiqxc lckddrruqd (rtcwzpjtrc, aufmberdxp - hhgzmzadup) View more | ||||||
Not Applicable | - | hyrjdsfpyj(nvovakfsnd) = zasnkvpxvt ungamrumnt (zusvrswxhw, -8.1% - -7.9%) View more | Positive | 01 Feb 2011 | |||
Not Applicable | Rhinitis, Allergic, Perennial nNO | nEos | 31 | Oral Levocetirizine (LC) 5mg | xmgercqmbj(oipqqxwbjz) = cgozdmmkhw wlumkptpxo (lynrokjmmg ) | Positive | 01 Feb 2010 | |
Phase 4 | 580 | placebo | ssjfpbnbrc(ppdoiwxlom) = fcruwgdwww lysvcjiofk (ppoqfbuzis, 3.44) View more | - | 17 Nov 2009 | ||
Phase 3 | 466 | (Levocetirizine) | zsdttjlztg = svhqogztly xcicsskhwh (iqwdhlklhl, ahcmufinkf - eamtxnaimq) View more | - | 14 Oct 2009 | ||
(Cetirizine) | zsdttjlztg = exksenoruz xcicsskhwh (iqwdhlklhl, gvkhjtmccb - niwdlmtogu) View more |